Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 10/20 | 0.73 |
| ▸ | DRD2 | P14416 | 9/20 | 0.73 |
| ▸ | DRD3 | P35462 | 9/20 | 0.73 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4616926 | 0.86 | ADRA1A (0.62) | ADRA1ADRD2DRD3HTR1A | |
| SCHEMBL978209 | 0.83 | DRD2 (0.58) | ADRA1ADRD2DRD3KDM4EHTR1A | |
| SCHEMBL74384 | 0.83 | ADRA1A (0.85) | ADRA1ADRD2DRD3ADRA1BADRA1D | |
| SCHEMBL8013505 | 0.83 | DRD2 (0.65) | ADRA1ADRD2DRD3HTR1A | |
| SCHEMBL976546 | 0.82 | DRD2 (0.57) | ADRA1ADRD2DRD3KCNH2HTR1A | |
| SCHEMBL8010491 | 0.82 | DRD2 (0.60) | ADRA1ADRD2DRD3KCNH2HTR1A | |
| SCHEMBL28007048 | 0.80 | HRH3 (0.54) | ADRA1ADRD2DRD3 | |
| SCHEMBL27263295 | 0.80 | ADRA1A (0.55) | ADRA1ADRD2DRD3ADRA1BADRA1D | |
| SCHEMBL8010266 | 0.79 | HTR1A (0.55) | ADRA1ADRD2DRD3HTR1A | |
| SCHEMBL8133702 | 0.79 | DRD2 (0.55) | ADRA1ADRD2DRD3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875287-B2 | 99mTc-8-[3-({2-[4-(2-methoxy-phenyl)-piperazine -1-yl]-ethyl}-pyridin-2-yl-amino)-propyl]-[1,2,5,8]dithiadiazecan-6-one; 5-HT1A selective serotonin receptors;receptivity; nonhydrolyzing; radiopharmaceuticals;scanning the brain; neurogenitive deseases; nervous system disorders | KOREA ATOMIC ENERGY RESEARCH INSTITUTE (KR) | 2011-01-25 | — | — | US | disclosed |
| US-20070036715-A1 | 99mTc-8-[3-({2-[4-(2-methoxy-phenyl)-piperazine -1-yl]-ethyl}-pyridin-2-yl-amino)-propyl]-[1,2,5,8]dithiadiazecan-6-one; 5-HT1A selective serotonin receptors;receptivity; nonhydrolyzing; radiopharmaceuticals;scanning the brain; neurogenitive deseases; nervous system disorders | KOREA ATOMIC ENERGY RESEARCH INSTITUTE (KR) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070036715-A1 | 99mTc-8-[3-({2-[4-(2-methoxy-phenyl)-piperazine -1-yl]-ethyl}-pyridin-2-yl-amino)-propyl]-[1,2,5,8]dithiadiazecan-6-one; 5-HT1A selective serotonin receptors;receptivity; nonhydrolyzing; radiopharmaceuticals;scanning the brain; neurogenitive deseases; nervous system disorders | HTR1A, HTR2A, HTR5A | ADRA1A 35/4885DRD2 137/4885DRD3 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.